Antibiotice S.A.

BVB:ATB Stock Report

Market Cap: RON 1.7b

Antibiotice Management

Management criteria checks 1/4

Antibiotice's CEO is Ioan Nani, appointed in Jan 2009, has a tenure of 16.08 years. directly owns 0% of the company’s shares, worth RON3.83K. The average tenure of the management team and the board of directors is 5.2 years and 1.1 years respectively.

Key information

Ioan Nani

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure16.1yrs
CEO ownership0.0002%
Management average tenure5.2yrs
Board average tenure1.1yrs

Recent management updates

Recent updates

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 23
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Jun 07
Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

Jan 30
Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

Jan 13
We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Aug 16
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Is Antibiotice (BVB:ATB) A Risky Investment?

Jun 08
Is Antibiotice (BVB:ATB) A Risky Investment?

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Feb 11
Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Jan 12
Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 16
Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 24
Is Antibiotice (BVB:ATB) Using Too Much Debt?

CEO

Ioan Nani (65 yo)

16.1yrs

Tenure

Mr. Ioan Nani serves as General Manager, General Director and Non-Independent Director at Antibiotice S.A. since 2009 and has been its Vice Chairman. He served as Non-Independent Vice President of Board at...

Leadership Team

NamePositionTenureCompensationOwnership
Ioan Nani
GM, General Director16.1yrsno data0.00023%
RON 3.8k
Paula-Luminita Coman
Executive Director of Financial & Financial Managerno datano datano data
Eugen Osadet
Engineering & Investment Director25.1yrsno datano data
Cornelia Moraru
Investors Relation Officer and Executive Director of Technical & Production2.1yrsno datano data
Liviu Vatavu
Executive Director of Legal & Corporate Governance5.2yrsno datano data
Ovidiu Bataga
Executive Director of National Salesno datano datano data
Mihaela Murariu
Executive Director of Human Resource2.4yrsno datano data

5.2yrs

Average Tenure

56yo

Average Age

Experienced Management: ATB's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ioan Nani
GM, General Director16.1yrsno data0.00023%
RON 3.8k
Ionut-Sebastian Iavor
Chairman1.1yrsno datano data
Mihai Trifu
Independent Non-Executive Director3.7yrsno datano data
Catalin Popescu
Independent Non-Executive Director3.7yrsno datano data
Catalin Lungu
Independent Director1.1yrsno datano data
Aurelia Talpos
Director1.1yrsno datano data
Raluca Puiu
Director1.1yrsno datano data
Viorela Zaharia
Directorno datano datano data

1.1yrs

Average Tenure

48.5yo

Average Age

Experienced Board: ATB's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/15 06:15
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Antibiotice S.A. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raluca NegoescuAlpha Finance Romania
Vladimira UrbankovaErste Group Bank AG
Roxana DascaluSSIF IEBA Trust SA